Login to Your Account



ASCO 2012

Biomarker Selection: Be an Early Bird? Or a Late Arriver?

By Anette Breindl
Science Editor

Monday, June 11, 2012

Co-developing a targeted therapeutic with a companion diagnostic can be crowned with spectacular success. But how early in development patients should be selected based on such a biomarker is a complex question. The story of Pfizer Inc.'s Xalkori (crizotinib) illustrates several of the issues that need to be considered during the development of such combinations.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription